宜明昂科-B(01541)：IMM0306治疗视神经嵴髓炎谱系疾病的IB期临床试验完成首例患者给药GOLDLION HOLD (00533) received a privatization proposal from Chairman Zeng Zhiming at a premium of approximately 24.85%. Resumes trading on December 18th. IMMUNEONCO-B (01541): The IB phase clinical trial for IMM0306 in treating optic nerve myelitis spectrum diseases has completed administration to the first patient.
[Significant Events]
Alibaba-W (09988): Plans to sell Silver Tai.
IMMUNEONCO-B (01541): The IB phase clinical trial for IMM0306 in treating optic nerve myelitis spectrum diseases has completed administration to the first patient.
GOLDLION HOLD (00533) received a privatization proposal from Chairman Zeng Zhiming at a premium of approximately 24.85%, with trading resuming on December 18.
Xintai Medical (02291): The ScienCrown transcatheter aortic valve implantation system has obtained a medical instruments registration certificate.
HANSOH PHARMA (03692): The injectable HS-20110 has received a clinical trial approval notice issued by the National Medical Products Administration.
KINGKEY FIN INT (01468) plans to establish a joint venture company focusing on the Operation and management of graphics processing unit server clusters in Thailand.
CHINA RISUN GP (01907): Shenzhen Venture Capital plans to additionally invest 0.8 billion yuan in Cangzhou Risun Chemical.
[Earnings Reports Data]
CHINAHONGQIAO (01378) issues earnings surprise, expecting annual Net income to increase by about 95% year-on-year.
China Coal Energy (01898) sold 0.256 billion tons of Commodity coal in the first 11 months, a year-on-year decrease of 1.9%.
Repurchase/Shareholding
KUAISHOU-W (01024) spent 19.4791 million HKD on December 17 to buy back 0.43 million shares.
AIA (01299) spent 0.455 billion HKD on December 17 to buy back 8.272 million shares.
TENCENT (00700) spent 0.703 billion Hong Kong dollars to repurchase 1.74 million shares on December 17.
For more details, please refer to 智通财经网().